The stock of Bioventus Inc (BVS) has gone up by 7.04% for the week, with a 2.47% rise in the past month and a -7.22% drop in the past quarter. The volatility ratio for the week is 7.14%, and the volatility levels for the past 30 days are 4.71% for BVS. The simple moving average for the last 20 days is 7.26% for BVS stock, with a simple moving average of 11.36% for the last 200 days.
Is It Worth Investing in Bioventus Inc (NASDAQ: BVS) Right Now?
The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BVS is 44.67M, and at present, short sellers hold a 1.94% of that float. On March 12, 2025, the average trading volume of BVS was 279.27K shares.
BVS) stock’s latest price update
Bioventus Inc (NASDAQ: BVS) has seen a rise in its stock price by 23.29 in relation to its previous close of 8.76. However, the company has experienced a 7.04% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-11 that Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford – Investor Relations Rob Claypoole – President & Chief Executive Officer Mark Singleton – Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Caitlin Cronin – Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Analysts’ Opinion of BVS
Many brokerage firms have already submitted their reports for BVS stocks, with JP Morgan repeating the rating for BVS by listing it as a “Neutral.” The predicted price for BVS in the upcoming period, according to JP Morgan is $13 based on the research report published on December 17, 2024 of the previous year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see BVS reach a price target of $7. The rating they have provided for BVS stocks is “Buy” according to the report published on December 07th, 2023.
Craig Hallum gave a rating of “Buy” to BVS, setting the target price at $6 in the report published on August 09th of the previous year.
BVS Trading at 6.20% from the 50-Day Moving Average
After a stumble in the market that brought BVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.90% of loss for the given period.
Volatility was left at 4.71%, however, over the last 30 days, the volatility rate increased by 7.14%, as shares surge +0.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.12% upper at present.
During the last 5 trading sessions, BVS rose by +7.04%, which changed the moving average for the period of 200-days by +75.32% in comparison to the 20-day moving average, which settled at $10.07. In addition, Bioventus Inc saw 2.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BVS starting from Singleton Mark Leonard, who sale 6,498 shares at the price of $10.19 back on Feb 18 ’25. After this action, Singleton Mark Leonard now owns 118,817 shares of Bioventus Inc, valued at $66,215 using the latest closing price.
D’Adamio Anthony, the SVP & General Counsel of Bioventus Inc, sale 4,380 shares at $10.19 during a trade that took place back on Feb 18 ’25, which means that D’Adamio Anthony is holding 118,178 shares at $44,632 based on the most recent closing price.
Stock Fundamentals for BVS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.67 for the gross margin
The net margin for Bioventus Inc stands at -0.06. The total capital return value is set at 0.05. Equity return is now at value -24.20, with -5.00 for asset returns.
Based on Bioventus Inc (BVS), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 1.38. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is 0.62.
Currently, EBITDA for the company is -49.55 million with net debt to EBITDA at -0.49. When we switch over and look at the enterprise to sales, we see a ratio of 1.21. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To sum up, Bioventus Inc (BVS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
